American Chemical Society
jm1c01928_si_002.csv (2.02 kB)

Development of a Novel, Small-Molecule Brain-Penetrant Histone Deacetylase Inhibitor That Enhances Spatial Memory Formation in Mice

Download (2.02 kB)
posted on 2022-02-08, 16:34 authored by Jawad B. Belayet, Sarah Beamish, Mizzanoor Rahaman, Samer Alanani, Rajdeep S. Virdi, David N. Frick, A. F. M. Towheedur Rahman, Joseph S. Ulicki, Sreya Biswas, Leggy A. Arnold, M. S. Rashid Roni, Eric Y. Cheng, Douglas A. Steeber, Karyn M. Frick, M. Mahmun Hossain
Histone acetylation is a prominent epigenetic modification linked to the memory loss symptoms associated with neurodegenerative disease. The use of existing histone deacetylase inhibitor (HDACi) drugs for treatment is precluded by their weak blood–brain barrier (BBB) permeability and undesirable toxicity. Here, we address these shortcomings by developing a new class of disulfide-based compounds, inspired by the scaffold of the FDA-approved HDACi romidepsin (FK288). Our findings indicate that our novel compound MJM-1 increases the overall level of histone 3 (H3) acetylation in a prostate cancer cell line. In mice, MJM-1 injected intraperitoneally (i.p.) crossed the BBB and could be detected in the hippocampus, a brain region that mediates memory. Consistent with this finding, we found that the post-training i.p. administration of MJM-1 enhanced hippocampus-dependent spatial memory consolidation in male mice. Therefore, MJM-1 represents a potential lead for further optimization as a therapeutic strategy for ameliorating cognitive deficits in aging and neurodegenerative diseases.